Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 3/2001

Open Access 01-06-2001 | Research article

Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression

Authors: Kanokwan Kittiniyom, Karen M Gorse, Fabienne Dalbegue, Jack H Lichy, Jeffery K Taubenberger, Irene F Newsham, PhD

Published in: Breast Cancer Research | Issue 3/2001

Login to get access

Abstract

We examined the stage specificity and heterogeneity of 18p11 alterations in a series of tumors representing 96 microdissected samples. Significant loss of heterozygosity (LOH) (63%) was found, with 56% occurring early in ductal carcinoma in situ. Although most cases indicated LOH was clonally inherited, heterogeneity for 18p LOH occurred in 27% of tumors. When compared with other LOH data, 18p LOH was found in conjunction with allelic deletion on 3p, 9p, 17p and 17q, while 13q, 16q, and 11p were less frequently associated. These analyses suggest chromosome 18p11 alteration is a common and early event in breast disease.
Literature
1.
Tran Y, Benbatoul K, Gorse K, Rempel S, Futreal A, Green M, Newsham I: Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. Oncogene. 1998, 17: 3499-3505. 10.1038/sj/onc/1202258.CrossRefPubMed
2.
Osborne RJ, Hamshere MG: A gemone-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res. 2000, 60: 3706-3712.PubMed
3.
Lichy JH, Zavar M, Tsai MM, O'Leary TJ, Taubenberger JK: Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast. Am J Pathol. 1998, 153: 271-278.CrossRefPubMedPubMedCentral
4.
Newsham IF, Gorse KM, Rempel SA, Luckey J, Golden JB, Bogler O: Use of horizontal ultrathin gel electrophoresis to analyze allelic deletions in chromsome band 11p15 in gliomas. Neuro-Oncol. 2000, 2: 1-5.PubMedPubMedCentral
5.
Ingvarsson S: Molecular genetics of breast cancer progression. Semin Cancer Biol. 1999, 9: 277-288. 10.1006/scbi.1999.0124.CrossRefPubMed
6.
Beckmann MW, Niederacher D, Schnurch H-G, Gusterson BA, Bender HG: Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med. 1997, 75: 429-439. 10.1007/s001090050128.CrossRefPubMed
7.
Lizard-Nacol S, Lidereau R, Collin F, Arnal M, Hahnel L, Roignot P, Cuisenier J, Guerrin J: Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy. Cancer Res. 1995, 55: 4416-4419.PubMed
8.
O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Clark GM, Allred DC: Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998, 90: 697-703. 10.1093/jnci/90.9.697.CrossRefPubMed
9.
Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS: Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science. 1996, 274: 2057-2059. 10.1126/science.274.5295.2057.CrossRefPubMed
10.
Ottesen GL, Graversen HP, Blichert TM, Zedeler K, Andersen JA: Ductal carcinoma in situ of the female breast: short-term results of a prospective nationwide study. Am J Surg Pathol. 1992, 16: 1183-1196.CrossRefPubMed
11.
Lichy JH, Dalbegue F, Zavar M, Washington C, Tsai MM, Sheng ZM, Taubenberger JK: Genetic heterogeneity in ductal carcinoma of the breast. Lab Invest. 2000, 80: 291-301.CrossRefPubMed
12.
Bonsing BA, Devilee P, Cleton-Jansen A-M, Kuipers-Dijkshoorn N, Fleuren GJ, Cornelisse CJ: Evidence for limited molecular genetic heterogeneity as defined by allelotyping and clonal analysis in nine metastatic breast carcinomas. Cancer Res. 1993, 53: 3804-3811.PubMed
13.
Anbazhagan R, Hiroaki F, Gabrielson E: Allelic loss of chromosomal arm 8p in breast cancer progression. Am J Pathol. 1998, 152: 815-819.PubMedPubMedCentral
14.
Marsh KL, Varley JM: Loss of heterozygosity at chromosome 9p in ductal carcinoma in situ and invasive carcinoma of the breast. Br J Cancer. 1998, 77: 1439-1447.CrossRefPubMedPubMedCentral
15.
16.
Fujii H, Szumel R, Marsh C, Zhou W, Gabrielson E: Genetic progression, histological grade and allelic loss in ductal carcinoma in situ of the breast. Cancer Res. 1996, 56: 5260-5265.PubMed
17.
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (London). 1994, 368: 753-756. 10.1038/368753a0.CrossRef
18.
Vos CB, ter Haar NT, Rosenberg C, Peterse JL, Cleton-Jansen AM, Cornelisse CJ, van de Vijver MJ: Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer. 1999, 81: 1410-1418. 10.1038/sj.bjc.6693372.CrossRefPubMedPubMedCentral
19.
Bonsing BA, Corver WE, Fleuren GJ, Cleton-Jansen AM, Devilee P, Cornelisse CJ: Allelotype analysis of flow-sorted breast cancer cells demonstrates genetically related diploid and aneuploid subpopulations in primary tumors and lymph node metastases. Genes Chrom Cancer. 2000, 28: 173-183. 10.1002/(SICI)1098-2264(200006)28:2<173::AID-GCC6>3.0.CO;2-1.CrossRefPubMed
20.
Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J: Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997, 57: 1597-1604.PubMed
21.
Emi M, Yoshimoto M, Sato T, Matsumoto S, Utada Y, Ito I, Minobe K, Iwase T, Katagiri T, Bando K, Akiyama F, Harada Y, Fukino K, Sakamoto G, Matsushima M, Iida A, Tada T, Saito H, Miki Y, Kasumi F, Nakamura Y: Allelic loss at 1p34, 13q12, 17p13.3 and 17q21.1 correlated with poor postoperative prognosis in breast cancer. Genes Chrom Cancer. 1999, 26: 134-141. 10.1002/(SICI)1098-2264(199910)26:2<134::AID-GCC5>3.3.CO;2-0.CrossRefPubMed
22.
Tran YK, Bogler O, Gorse K, Wieland I, Green MR, Newsham IF: A novel member of the NF2.ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 1999, 59: 35-43.PubMed
Metadata
Title
Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression
Authors
Kanokwan Kittiniyom
Karen M Gorse
Fabienne Dalbegue
Jack H Lichy
Jeffery K Taubenberger
Irene F Newsham, PhD
Publication date
01-06-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2001
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr294

Other articles of this Issue 3/2001

Breast Cancer Research 3/2001 Go to the issue

Commentary

The complexities of breast cancer desmoplasia

Commentary

More breast cancer genes?

Meeting report

Update on endocrine aspects of breast cancer: Report from the 23rd San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 6-9 December 2000

Commentary

Telomerase and breast cancer

Commentary

Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?

Review

Applications of microarray technology in breast cancer research
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits